Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 Business Wire - Tue Apr 7, 6:00AM CDT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) Business Wire - Mon Mar 30, 6:00AM CDT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference Business Wire - Tue Mar 3, 6:00AM CST

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting Business Wire - Tue Feb 10, 6:00AM CST

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot AP - Mon Feb 9, 3:06PM CST

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 Business Wire - Mon Feb 9, 3:01PM CST

Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV)...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook Business Wire - Thu Jan 8, 6:00AM CST

Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in Development...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire - Mon Jan 5, 6:00AM CST

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological...

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot AP - Mon Nov 17, 2025

Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

ENTA : 14.11 (+1.15%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 Business Wire - Mon Nov 17, 2025

Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic...

ENTA : 14.11 (+1.15%)

Barchart Exclusives

While the Stock Market Was Rallying, Palantir Stock Sold Off. Should You Buy the Dip in PLTR? Barchart - Sat Apr 11, 10:30AM CDT
Shares of the Alex Karp-led company nosedived by more than 14% on the ceasefire news. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.